KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash & Equivalents (2016 - 2025)

Eli Lilly (LLY) has disclosed Cash & Equivalents for 17 consecutive years, with $7.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 122.4% year-over-year to $7.3 billion, compared with a TTM value of $7.3 billion through Dec 2025, up 122.4%, and an annual FY2025 reading of $7.3 billion, up 122.4% over the prior year.
  • Cash & Equivalents was $7.3 billion for Q4 2025 at Eli Lilly, down from $9.8 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $9.8 billion in Q3 2025 and bottomed at $2.1 billion in Q4 2022.
  • Average Cash & Equivalents over 5 years is $3.5 billion, with a median of $3.2 billion recorded in 2021.
  • The sharpest move saw Cash & Equivalents plummeted 45.87% in 2022, then surged 190.65% in 2025.
  • Year by year, Cash & Equivalents stood at $3.8 billion in 2021, then tumbled by 45.87% to $2.1 billion in 2022, then skyrocketed by 36.36% to $2.8 billion in 2023, then grew by 15.94% to $3.3 billion in 2024, then surged by 122.4% to $7.3 billion in 2025.
  • Business Quant data shows Cash & Equivalents for LLY at $7.3 billion in Q4 2025, $9.8 billion in Q3 2025, and $3.4 billion in Q2 2025.